NCT06518382 2026-04-15
Tumor-microenvironment Spatial Interaction to Identify Markers of Resistance to Therapy in HER2+ Breast Cancer Patients
IRCCS Ospedale San Raffaele
Recruiting
Clinical Trials
11 trialsNCT06754059 2025-01-01
Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC
Fujian Medical University Union Hospital
Recruiting
NCT06722599 2024-12-09
LRNacHER2
Peking University People's Hospital
Recruiting
NCT06722612 2024-12-09
TaxCbHER2
Peking University People's Hospital
Recruiting
NCT06711055 2024-12-02
TaxHER
Peking University People's Hospital
Recruiting
NCT06711068 2024-12-02
TaxDHER2
Peking University People's Hospital
Recruiting
NCT06700369 2024-11-25
NacHER2
Peking University People's Hospital
Recruiting
NCT06693024 2024-11-20
NeraHER2
Peking University People's Hospital
Recruiting
NCT06693037 2024-11-20
nonPHER
Peking University People's Hospital
Recruiting
NCT05433753 2024-03-25
Asian Multicenter Prospective Study in HER2 Positive Early Breast Cancer for Detecting MRD by ctDNA;HARMONY Study
National Cancer Center, Japan
Recruiting
NCT04638725 2022-08-03
SIGHER
Institut de cancérologie Strasbourg Europe
Recruiting